Standout Papers

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the N... 2011 2026 2016 2021 7.0k
  1. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011)
    Marilyn S. Albert, Steven T. DeKosky et al. Alzheimer s & Dementia
  2. The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease (2013)
    Marilyn S. Albert, Steven T. DeKosky et al. FOCUS The Journal of Lifelong Learning in Psychiatry
  3. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019)
    Justin M. Long, David M. Holtzman Cell
  4. Alzheimer disease (2021)
    David S. Knopman, Hélène Amieva et al. Nature Reviews Disease Primers
  5. TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model (2015)
    Yaming Wang, Marina Cella et al. Cell
  6. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards (2006)
    Vladimir Hachinski, Costantino Iadecola et al. Stroke
  7. Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier (2000)
    Masayoshi Shibata, Shinya Yamada et al. Journal of Clinical Investigation
  8. The Role of Apolipoprotein E in Alzheimer's Disease (2009)
    Jungsu Kim, Jacob M. Basak et al. Neuron
  9. Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle (2009)
    Miranda M. Lim, Randall J. Bateman et al. Science
  10. Alzheimer’s Disease: The Challenge of the Second Century (2011)
    David M. Holtzman, John C. Morris et al. Science Translational Medicine
  11. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease (2001)
    Ronald B. DeMattos, Kelly R. Bales et al. Proceedings of the National Academy of Sciences
  12. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums (2018)
    Steven E. Arnold, Zoe Arvanitakis et al. Nature Reviews Neurology
  13. Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo (2005)
    John R. Cirrito, Kelvin A. Yamada et al. Neuron
  14. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A (2012)
    Robert D. Bell, Ethan A. Winkler et al. Nature
  15. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans (2005)
    Anne M. Fagan, Mark A. Mintun et al. Annals of Neurology
  16. Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance (2011)
    Joseph M. Castellano, Jungsu Kim et al. Science Translational Medicine
  17. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease (2008)
    Melanie Meyer‐Luehmann, Tara L. Spires‐Jones et al. Nature
  18. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease (2017)
    Tyler K. Ulland, Wilbur M. Song et al. Cell
  19. Hallmarks of neurodegenerative diseases (2023)
    David M. Wilson, Mark Cookson et al. Cell
  20. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease (2000)
    David M. Holtzman, Kelly R. Bales et al. Proceedings of the National Academy of Sciences
  21. ApoE Promotes the Proteolytic Degradation of Aβ (2008)
    Qingguang Jiang, Shweta Mandrekar et al. Neuron
  22. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model (2002)
    Jean‐Cosme Dodart, Kelly R. Bales et al. Nature Neuroscience
  23. Neuronal activity regulates the regional vulnerability to amyloid-β deposition (2011)
    Adam W. Bero, Ping Yan et al. Nature Neuroscience
  24. Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults (2007)
    Anne M. Fagan, Catherine M. Roe et al. Archives of Neurology
  25. Biomarker Modeling of Alzheimer’s Disease (2013)
    Clifford R. Jack, David M. Holtzman Neuron
  26. Sleep and Alzheimer disease pathology—a bidirectional relationship (2013)
    Yo‐El S. Ju, Brendan P. Lucey et al. Nature Reviews Neurology
  27. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging (2009)
    John C. Morris, Catherine M. Roe et al. Annals of Neurology
  28. Selective Vulnerability of Late Oligodendrocyte Progenitors to Hypoxia–Ischemia (2002)
    Stephen A. Back, Byung Hee Han et al. Journal of Neuroscience
  29. Apolipoprotein E in Alzheimer's disease and other neurological disorders (2011)
    Philip B. Verghese, Joseph M. Castellano et al. The Lancet Neurology
  30. apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain (2008)
    Rashid Deane, Abhay P. Sagare et al. Journal of Clinical Investigation
  31. Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease (2012)
    David M. Holtzman, Joachim Herz et al. Cold Spring Harbor Perspectives in Medicine
  32. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques (2016)
    Yaming Wang, Tyler K. Ulland et al. The Journal of Experimental Medicine
  33. Mechanisms linking circadian clocks, sleep, and neurodegeneration (2016)
    Erik S. Musiek, David M. Holtzman Science
  34. Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System (2006)
    Robert D. Bell, Abhay P. Sagare et al. Journal of Cerebral Blood Flow & Metabolism
  35. Three dimensions of the amyloid hypothesis: time, space and 'wingmen' (2015)
    Erik S. Musiek, David M. Holtzman Nature Neuroscience
  36. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis (2019)
    Suzanne E. Schindler, James G. Bollinger et al. Neurology
  37. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease (2016)
    Matthew R. Brier, Brian A. Gordon et al. Science Translational Medicine
  38. Sleep Quality and Preclinical Alzheimer Disease (2013)
    Yo‐El S. Ju, Jennifer McLeland et al. JAMA Neurology
  39. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans (2019)
    Jerrah K. Holth, Sarah K. Fritschi et al. Science
  40. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease (2009)
    Richard J. Perrin, Anne M. Fagan et al. Nature
  41. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease (2016)
    Myles R. Minter, Can Zhang et al. Scientific Reports
  42. Loss of Intranetwork and Internetwork Resting State Functional Connections with Alzheimer's Disease Progression (2012)
    Matthew R. Brier, John B. Thomas et al. Journal of Neuroscience
  43. Proteopathic tau seeding predicts tauopathy in vivo (2014)
    Brandon B. Holmes, Jennifer L. Furman et al. Proceedings of the National Academy of Sciences
  44. Trans-cellular Propagation of Tau Aggregation by Fibrillar Species (2012)
    Najla Kfoury, Brandon B. Holmes et al. Journal of Biological Chemistry
  45. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions (2013)
    Philip B. Verghese, Joseph M. Castellano et al. Proceedings of the National Academy of Sciences
  46. Neuronal activity regulates extracellular tau in vivo (2014)
    Kaoru Yamada, Jerrah K. Holth et al. The Journal of Experimental Medicine
  47. Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels (2017)
    Yo‐El S. Ju, Sharon Ooms et al. Brain
  48. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study (2013)
    Stephanie J. B. Vos, Chengjie Xiong et al. The Lancet Neurology
  49. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018)
    Yang Shi, David M. Holtzman Nature reviews. Immunology
  50. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis (2017)
    Vitaliy Ovod, Kwasi G. Mawuenyega et al. Alzheimer s & Dementia
  51. Sleep, circadian rhythms, and the pathogenesis of Alzheimer Disease (2015)
    Erik S. Musiek, David D. Xiong et al. Experimental & Molecular Medicine
  52. Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors (2019)
    Chanung Wang, David M. Holtzman Neuropsychopharmacology
  53. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease (2018)
    Erik S. Musiek, John C. Morris et al. JAMA Neurology
  54. Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. (1992)
    Marı́a Gasset, M. A. Baldwin et al. Proceedings of the National Academy of Sciences
  55. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy (2023)
    Xiaoying Chen, Maria Firulyova et al. Nature
  56. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia (2021)
    Chao Wang, Monica Xiong et al. Neuron
  57. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol (2021)
    Hao Wang, Joshua A. Kulas et al. Proceedings of the National Academy of Sciences
  58. Emerging diagnostics and therapeutics for Alzheimer disease (2023)
    Wade Self, David M. Holtzman Nature Medicine
  59. ApoE Cascade Hypothesis in the pathogenesis of Alzheimer’s disease and related dementias (2022)
    Yuka A. Martens, Na Zhao et al. Neuron
  60. Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease (2023)
    Aura Ferreiro, JooHee Choi et al. Science Translational Medicine
  61. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis (2021)
    Tim West, Kristopher M. Kirmess et al. Molecular Neurodegeneration
  62. APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease (2022)
    Samira Parhizkar, David M. Holtzman Seminars in Immunology
  63. Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategies (2024)
    Dong-oh Seo, David M. Holtzman Experimental & Molecular Medicine
  64. Disease staging of Alzheimer’s disease using a CSF-based biomarker model (2024)
    Gemma Salvadó, Kanta Horie et al. Nature Aging
  65. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease (2025)
    Kanta Horie, Gemma Salvadó et al. Nature Medicine

Immediate Impact

48 by Nobel laureates 76 from Science/Nature 299 standout
Sub-graph 1 of 15

Citing Papers

Nasopharyngeal lymphatic plexus is a hub for cerebrospinal fluid drainage
2024 StandoutNature
Neurotoxic reactive astrocytes induce cell death via saturated lipids
2021 StandoutNature
9 intermediate papers

Works of David M. Holtzman being referenced

In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins
2004
Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (−/−), and Human apoE Transgenic Mice
1999
and 25 more

Author Peers

Author Last Decade Papers Cites
David M. Holtzman 52505 26534 20088 22999 574 96.4k
Bradley T. Hyman 59624 31994 23741 20733 723 111.3k
Colin L. Masters 51387 30676 14532 10156 1.1k 81.0k
Kaj Blennow 64391 32614 40289 21502 2.0k 118.7k
Henrik Zetterberg 45261 25444 27654 16508 1.9k 92.3k
John Hardy 48936 34144 8107 17634 871 90.9k
Dennis W. Dickson 47638 24716 21829 23462 1.2k 100.8k
Bengt Winblad 27211 16041 22729 8988 1.2k 77.3k
Eliezer Masliah 46485 33703 7184 23030 841 103.4k
Dennis J. Selkoe 83348 48869 7699 17587 475 113.9k
John Q. Trojanowski 68747 45584 26065 28772 1.1k 148.3k

All Works

Loading papers...

Rankless by CCL
2026